Home > Annual Financials > GLAND PHARMA

GLAND PHARMA Financial Statement Analysis
[BOM: 543245|NSE : GLAND]

The Revenues of GLAND PHARMA have increased by 31.51% YoY .
The Earnings Per Share (EPS) of GLAND PHARMA has increased by 22.17 % YoY.
REVENUES
OPERATING MARGIN
PROFIT AFTER TAX
EPS
ROCE

GLAND PHARMA Last 5 Annual Financial Results
[BOM: 543245|NSE : GLAND]

ConsolidatedMar2021
Mar2020
Revenues ₹3,463 Cr₹2,633 Cr
Expenses ₹2,161 Cr₹1,678 Cr
Operating Profit (Excl OI) ₹1,302 Cr₹955 Cr
Other Income ₹135 Cr₹139 Cr
Interest ₹3.41 Cr₹7.18 Cr
Depreciation ₹99 Cr₹95 Cr
Profit Before Tax ₹1,335 Cr₹993 Cr
Profit After Tax ₹997 Cr₹773 Cr
Consolidated Net Profit ₹997 Cr₹773 Cr
Earnings Per Share (Rs)₹60.94₹49.88
PAT Margin (%)28.7929.35
ROE(%)20.9721.29
ROCE(%)28.0027.39
Total Debt/Equity(x)0.000.00

Key Financials

Market Cap : ₹ 42,402.8 Cr
Revenue (TTM) : ₹ 4,400.7 Cr
Net Profit(TTM) : ₹ 1,211.7 Cr
EPS (TTM) : ₹ 73.6
P/E (TTM) : 35.0

Industry Peers & Returns1W1M1Y
GLAND PHARMA -4.7% -8.6% -27.2%
SUN PHARMACEUTICAL INDUSTRIES 0.8% -1.3% 22.7%
DIVIS LABORATORIES 0.4% 4.2% -18.1%
DR REDDYS LABORATORIES -0.1% 6.1% -19%
CIPLA 3.4% -2.8% -4.2%
PIRAMAL ENTERPRISES 3.2% -3.5% -29.5%
CADILA HEALTHCARE 2.6% 2.6% -43.5%
TORRENT PHARMACEUTICALS 1.4% 3.9% -1.9%
ALKEM LABORATORIES 2.7% -1.9% -4.2%


GLAND PHARMA Revenues
[BOM: 543245|NSE : GLAND]

Y-o-Y

31.51 %

5 Yr CAGR

31.51 %

Years Revenues % Change
Mar2021 ₹3,463 Cr
31.51
Mar2020 ₹2,633 Cr -


GLAND PHARMA Operating Profit
[BOM: 543245|NSE : GLAND]

Y-o-Y

36.29 %

5 Yr CAGR

36.29 %

Years Operating Profit % Change
Mar2021 ₹1,302 Cr
36.29
Mar2020 ₹955 Cr -

Operating Margins
Y-o-Y

3.67 %

5 Yr CAGR

3.67 %

Years Operating Margin% % Change
Mar2021 37.61%
3.67
Mar2020 36.28% -

GLAND PHARMA Profit After Tax
[BOM: 543245|NSE : GLAND]

Y-o-Y

29.00 %

5 Yr CAGR

29.00 %

Years Profit After Tax % Change
Mar2021 ₹997 Cr
29.00
Mar2020 ₹773 Cr -

PAT Margins
Y-o-Y

-1.91 %

5 Yr CAGR

-1.91 %

Years PAT Margin(%) % Change
Mar2021 28.79 %
-1.91
Mar2020 29.35 % -

GLAND PHARMA Earnings Per Share (EPS)
[BOM: 543245|NSE : GLAND]

Y-o-Y

22.17 %

5 Yr CAGR

22.17 %

Years EPS % Change
Mar2021 ₹61
22.17
Mar2020 ₹50 -

GLAND PHARMA Return on Capital Employed (ROCE)
[BOM: 543245|NSE : GLAND]

Y-o-Y

2.23 %

5 Yr CAGR

2.23 %

Years ROCE % Change
Mar2021 28%
2.23
Mar2020 27.39% -

GLAND PHARMA Share Price vs Sensex

Current Share Price : ₹2,574.6
Current MarketCap: ₹ 42,402.8 Cr
Updated EOD on :Jul 06,2022

Share Price Returns(%) 1 Week 1 Month 1 Year
GLAND PHARMA

-4.7%

-8.6%

-27.2%

SENSEX

-0.1%

-4.7%

1.2%

GLAND PHARMA related INDICES

BSE Indices1W1M1Y
S&P BSE HEALTHCARE 0.2% -1.2% -14.9%
S&P BSE ALLCAP -0% -4.4% 0.1%
S&P BSE 500 -0% -4.3% -0.1%
S&P BSE LARGE MIDCAP -0.1% -4.2% 0.3%
S&P BSE 250 LARGEMIDCAP -0.1% -4.3% 0.2%
NSE Indices1W1M1Y
NIFTY MNC 1.4% -0.4% 2.5%
NIFTY NEXT 50 1% -2.5% -3.1%
NIFTY PHARMA 0.2% -1.5% -14.5%
NIFTY 100 EQUAL WEIGHT 0.1% -3.2% -1.8%
NIFTY500 MULTICAP 50:25:25 0% -4.7% -0.7%

You may also like the below Video Courses


FAQ about GLAND PHARMA Financials


How the annual revenues of GLAND PHARMA have changed ?

The Revenues of GLAND PHARMA have increased by 31.51% YoY .

How the Earnings per Share (EPS) of GLAND PHARMA have changed?

The Earnings Per Share (EPS) of GLAND PHARMA has increased by 22.17 % YoY .



SEBI Research Analyst
The Founder of this website, Mr. Rohit Katiyar is registered with SEBI as a Research Analyst [INH000007377].